Literature DB >> 21213045

Proline rich polypeptide (PRP-1) increases the superoxide-producing and ferrihemoglobin reducing activities of cytochrome B(558) isoforms from human lymphosarcoma tissue cells.

G M Simonyan1, K A Galoian, R M Simonyan, M A Simonyan, A A Galoyan.   

Abstract

The two cytochromes (cyt) b(558) of acidic nature, one-95-100 kDa and another one, 60-70 kDa were isolated for the first time from the human's lymphosarcoma tissue cells using gel filtration and ion exchange chromatography. These hemoproteins possess NADPH dependent O(2)(-)-producing and ferrihemoglobin-reducing activities. The incubation of neuropeptide PRP-1 (5 μg) with cytochrome b(558), caused elevation of these activities. The gel filtration results indicated possible binding of PRP-1 to these cytochromes b(558). PRP-1 activated both NADPH dependent O(2)(-)-producing and ferriHb-reducing activities of the cyt b(1)(558) and cyt b(2)(558), obtained from human lymphosarcoma tissue cells. One can assume that PRP-1 associated with cyt b(558) on the surface of the tumor cells by increasing both NADPH dependent O(2)(-)-producing and ferriHb-reducing activities of cyt b(558), increases the oxidation- reduction status. Changing the oxidation-reduction status and oxygen homeostasis of the tumor cells by PRP-1 can serve as one of the possible explanation of antitumorigenic effect of this cytokine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21213045     DOI: 10.1007/s11064-010-0389-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  12 in total

1.  NMR solution structure of the tandem Src homology 3 domains of p47phox complexed with a p22phox-derived proline-rich peptide.

Authors:  Kenji Ogura; Ikuo Nobuhisa; Satoru Yuzawa; Ryu Takeya; Shinnosuke Torikai; Kazuya Saikawa; Hideki Sumimoto; Fuyuhiko Inagaki
Journal:  J Biol Chem       Date:  2005-12-02       Impact factor: 5.157

2.  Immunoaffinity purification of human phagocyte flavocytochrome b and analysis of conformational dynamics.

Authors:  Ross M Taylor; Algirdas J Jesaitis
Journal:  Methods Mol Biol       Date:  2007

3.  Antioxidant and electron donating function of hypothalamic polypeptides: galarmin and Gx-NH2.

Authors:  L A Tavadyan; K A Galoian; L A Harutunyan; H G Tonikyan; A A Galoyan
Journal:  Neurochem Res       Date:  2010-05-04       Impact factor: 3.996

Review 4.  Mechanism of the tumor suppressive effect of MnSOD overexpression.

Authors:  Larry W Oberley
Journal:  Biomed Pharmacother       Date:  2005-03-19       Impact factor: 6.529

5.  An NAD(P)H oxidase regulates growth and transcription in melanoma cells.

Authors:  Sukhdev S Brar; Thomas P Kennedy; Anne B Sturrock; Thomas P Huecksteadt; Mark T Quinn; A Richard Whorton; John R Hoidal
Journal:  Am J Physiol Cell Physiol       Date:  2002-06       Impact factor: 4.249

6.  Expression of cytochrome b558 on B cell- and CD 30 positive-lymphomas.

Authors:  M Shiota; S Mori; S Imajoh-Ohmi; M Nakamura; S Kanegasaki; H Serizawa; T Izumo; T Uehara
Journal:  Pathol Res Pract       Date:  1993-11       Impact factor: 3.250

7.  Inhibition of NADPH oxidase activity promotes differentiation of B16 melanoma cells.

Authors:  Yunfeng Zhao; Jianfeng Liu; Kenneth E McMartin
Journal:  Oncol Rep       Date:  2008-05       Impact factor: 3.906

Review 8.  p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases.

Authors:  Jame El-Benna; Pham My-Chan Dang; Marie Anne Gougerot-Pocidalo; Jean Claude Marie; Francoise Braut-Boucher
Journal:  Exp Mol Med       Date:  2009-04-30       Impact factor: 8.718

9.  Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells.

Authors:  Karina Galoian; Sean Scully; Armen Galoyan
Journal:  Neurochem Res       Date:  2008-07-09       Impact factor: 3.996

10.  Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma.

Authors:  Karina Galoian; Sean Scully; George McNamara; Patrick Flynn; Armen Galoyan
Journal:  Neurochem Res       Date:  2009-12       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.